Medical Equipment Stocks Technical Reports -- St. Jude Medical, Wright Medical, Edwards Lifesciences, and Steris

Aug 23, 2016, 08:05 ET from Chelmsford Park SA

NEW YORK, August 23, 2016 /PRNewswire/ --

This morning's stocks in focus on belong in the Healthcare sector which rose 0.3% in midday trading on Monday, August 22, 2016. As per Forbes, the Health Care Select Sector SPDR ETF (XLV) climbed 0.2%, up 4.21% on an YTD basis. Let us now review the following Medical Appliances and Equipment equities and see how they fared at the close: St. Jude Medical Inc. (NYSE: STJ), Wright Medical Group N.V. (NASDAQ: WMGI), Edwards Lifesciences Corp. (NYSE: EW), and Steris PLC (NYSE: STE). Download the free research reports on these stocks today:

St. Jude Medical  

Shares in St. Paul, Minnesota headquartered St. Jude Medical Inc. ended Monday's session at $82.88, which was a slight decline of 0.12%. The stock recorded a trading volume of 2.30 million shares. The Company's shares have gained 1.44% in the last one month, 9.07% in the previous three months, and 35.50% since the start of this year. The stock is trading 3.05% above its 50-day moving average and 25.92% above its 200-day moving average. Moreover, shares of St. Jude Medical, which together with its subsidiaries, develops, manufactures, and distributes cardiovascular medical devices for cardiac rhythm management, cardiovascular, and atrial fibrillation therapy areas worldwide, have a Relative Strength Index (RSI) of 56.55.

On August 3rd, 2016, St. Jude Medical announced that its Board of Directors declared a Q3 dividend of $0.31 per common share of the company's stock. The dividend is payable on October 28th, 2016, to shareholders of record at the close of business on September 30th, 2016. See our free and comprehensive research report on STJ at:

Wright Medical Group  

Amsterdam, the Netherlands headquartered Wright Medical Group N.V.'s stock rose 1.82%, closing the day at $25.18 with a total volume of 1.10 million shares traded. The Company's shares have advanced 15.93% in the last month, 30.87% over the previous three months, and 4.14% on an YTD basis. The stock is trading 21.56% above its 50-day moving average and 26.67% above its 200-day moving average. Additionally, shares of Wright Medical Group, which designs, manufactures, markets, and sells orthopedic products in the US, Europe, and internationally, have an RSI of 73.33.

On August 3rd, 2016, the company reported that net sales from continuing operations totaled $170.7 million during Q2 ended June 26th, 2016. Combined pro forma net sales from continuing operations totaled $150.2 million during Q2 2015. Wright Medical's net loss from continuing operations for Q2 2016 totaled $42.0 million, or $(0.41) per diluted share. WMGI free research report PDF is just a click away at:

Edwards Lifesciences  

On Monday, shares in Irvine, California headquartered Edwards Lifesciences Corp. recorded a trading volume of 1.36 million shares. The stock ended the day 0.91% lower at $116.99. The Company's shares have gained 10.11% in the past month, 16.97% in the previous three months, and 48.13% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 10.14% and 25.54%, respectively. Furthermore, shares of Edwards Lifesciences, which provides products and technologies to treat structural heart disease and critically ill patients worldwide, have an RSI of 68.69.

On July 27th, 2016, research firm Bank of America/ Merrill upgraded the Company's stock rating from 'Neutral' to 'Buy'.

On August 18th, 2016, Edwards Lifesciences announced the U.S. Food and Drug Administration approval to expand use of the Edwards SAPIEN 3 transcatheter heart valve for the treatment of patients suffering from severe, symptomatic aortic stenosis who have been determined by a Heart Team to be at intermediate risk for open-heart surgery. The SAPIEN 3 valve is the first transcatheter aortic valve replacement therapy to obtain this indication in the US. Sign up for your complimentary report on EW at:


Leicester, the UK headquartered Steris PLC's stock saw a slight drop of 0.66%, finishing yesterday's session at $70.36 and with a total volume of 358,847 shares traded. The Company's shares have advanced 1.37% in the last one month and 2.80% over the previous three months. The stock is trading above its 50-day and 200-day moving averages by 1.67% and 0.59%, respectively. Additionally, shares of Steris, which develops, manufactures, and markets infection prevention, contamination control, microbial reduction, and surgical and gastrointestinal support products and services for healthcare, pharmaceutical, scientific, research, industrial, and governmental customers worldwide, have an RSI of 48.16.

On August 9th, 2016, Steris announced that Q1 FY17 revenue increased 45% to $638.4 million compared to $439.9 million in Q1 FY16. As reported, net income for Q1 was $48.4 million, or $0.56 per diluted share, compared to net income of $24.3 million, or $0.40 per diluted share, in Q1 FY16. Register for free on and download the latest research report on STE at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number:  +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA